{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:06:19Z","timestamp":1740107179301,"version":"3.37.3"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03509-9","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T22:23:32Z","timestamp":1731536612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of IL-17 inhibitors in hidradenitis suppurativa: an updated systematic review and meta-analysis including the BE-HEARD trials"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5076-1364","authenticated-orcid":false,"given":"Mohammad Haris","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zayed","family":"Mohiyuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muiz Khan","family":"Tareen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Faizan","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Talha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"10378","key":"3509_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GB, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Bourboulis EJ, Villani AP, Schwinn A, Ru\u00ebff F (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747\u2013761","journal-title":"Lancet"},{"key":"3509_CR2","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GB, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ (2024) Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 403:2504\u20132519","journal-title":"Lancet"},{"issue":"11","key":"3509_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J et al (2021) Efficacy and Safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind placebo-controlled randomized clinical trial. JAMA Dermatolog 157(11):1279\u20131288","journal-title":"JAMA Dermatolog"},{"issue":"10","key":"3509_CR4","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/exd.14619","volume":"31","author":"AB Kimball","year":"2022","unstructured":"Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I, Jarvis P, Peters T, Roth L, Wieczorek G, Kolbinger F (2022) IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study. Exp Dermatol 31(10):1522\u20131532","journal-title":"Exp Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03509-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03509-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03509-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T23:05:19Z","timestamp":1731539119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03509-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":4,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3509"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03509-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"12"}}